** Brokerage BofA Global Research raises PT on drugmaker AbbVie ABBV.N to $223 from $200, a 5.4% upside to the stock's last close
** Maintains "neutral" rating
** PT raise in part due to ABBV signing a licensing deal earlier this week with Danish biotech Gubra GUBRA.CO to develop an obesity treatment that mimics pancreatic hormone amylin
** Brokerage says ABBV expects weight-loss of 15% to 20% as a stand-alone product with better tolerability and less lean-muscle loss than GLP-1 drugs
** Although late-entrants into the obesity drug market could struggle to compete with incumbents Novo Nordisk NOVOb.CO and Eli Lilly LLY.N, a suite of products and/or differentiation will help, BofA says
** Stock has risen 18.2% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。